ABSTRACT To circumvent aGVHD in the early phase after allogeneic stem cell transplantation but to provide GVL activity later on, we performed alloPBSCT with CD34+ selected grafts followed by

delayed add-back of CD3+ T cells. Ten consecutive patients having an HLA-identical sibling donor were enrolled on to this trial. Four patients were in first CR of high-risk ALL, another

four in first CR of AML, one was in second myeloid blast crisis of CML, and one was in PR of relapsed NHL. Conditioning consisted of 2 × 60 mg/kg CY plus 12 Gy TBI. G-CSF (Filgrastim)

mobilized peripheral cells were CD34+selected using the Isolex 300i system in nine patients and the CliniMacs system in one. Median CD34+ purity was 86%. A median of 2.8 × 106/kg CD34+ cells

50% of the starting dose. One of these patients died after a second T cell boost given on day +90 without concomitant immunosuppression due to grade IV intestinal aGVHD. Three others

developed cutaneous cGVHD. Taken together, T cell depletion by CD34+ selection does not impair rapid engraftment in the HLA-identical sibling donor setting. Using standard-dose CsA the risk

for acute GVHD seems to be minimized. Add-back of 2 × 106/kg CD3+ cells on day +60 with CsA protection is feasible. However, whether this is the optimal time point and number of T cells

remain to be further elucidated. _Bone Marrow Transplantation_ (2000) 25, Suppl. 2, S2–S5. Access through your institution Buy or subscribe This is a preview of subscription content, access

via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 12 print issues and online access $259.00 per year only $21.58 per issue Learn more Buy

this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: *

Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS HOW ADOPTIVE TRANSFER OF COMPONENTS OF THE DONOR IMMUNE

SYSTEM BOOSTS GVL AND PREVENTS GVHD IN HLA-HAPLOIDENTICAL HEMATOPOIETIC TRANSPLANTATION FOR ACUTE LEUKEMIA Article 11 January 2024 RESULTS OF A MULTICENTER PHASE I/II TRIAL OF TCRΑΒ AND

CD19-DEPLETED HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ADULT AND PEDIATRIC PATIENTS Article Open access 24 December 2021 SAFETY AND EFFICACY OF THE LOW-DOSE MEMORY

(CD45RA-DEPLETED) DONOR LYMPHOCYTE INFUSION IN RECIPIENTS OF ΑΒ T CELL-DEPLETED HAPLOIDENTICAL GRAFTS: RESULTS OF A PROSPECTIVE RANDOMIZED TRIAL IN HIGH-RISK CHILDHOOD LEUKEMIA Article 16

February 2021 AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Medizinische Klinik III, Universitätsklinik Benjamin Franklin, Freie Universität, Berlin, Germany W Knauf, T Fietz, H

Schrezenmeier & E Thiel Authors * W Knauf View author publications You can also search for this author inPubMed Google Scholar * T Fietz View author publications You can also search for

this author inPubMed Google Scholar * H Schrezenmeier View author publications You can also search for this author inPubMed Google Scholar * E Thiel View author publications You can also

search for this author inPubMed Google Scholar RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Knauf, W., Fietz, T., Schrezenmeier, H. _et al._ CD34

selected alloPBSCT and adoptive immunotherapy. _Bone Marrow Transplant_ 25 (Suppl 2), S2–S5 (2000). https://doi.org/10.1038/sj.bmt.1702342 Download citation * Published: 01 May 2000 * Issue

Date: 01 May 2000 * DOI: https://doi.org/10.1038/sj.bmt.1702342 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a

shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative KEYWORDS * CD34+ selection * delayed

add-back of T cells * aGVHD